Platelets and cancer-associated thrombosis

Seminars in Oncology

Volumn 41, Issue 3, 2014, Pages 302-310

  Connolly, Gregory C ^a   Phipps, Richard P ^b   Francis, Charles W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BIOLOGICAL MARKER; PADGEM PROTEIN; PLACEBO; THROMBOCYTE FACTOR 4;

ARTICLE; CANCER PATIENT; CLINICAL TRIAL; HUMAN; LOW DRUG DOSE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE VOLUME; THROMBOCYTOSIS; THROMBOSIS; VENOUS THROMBOEMBOLISM;

ANIMALS; ANTICOAGULANTS; BLOOD PLATELETS; HUMANS; NEOPLASMS; THROMBOSIS;

EID: 84904174930     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.04.009     Document Type: Article

References (60)

1. J.A. Heit, W.M. O'Fallon, and T.M. Petterson et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study Arch Intern Med 162 11 2002 1245 1248
2. A.A. Khorana, C.W. Francis, E. Culakova, N.M. Kuderer, and G.H. Lyman Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy J Thromb Haemost 5 3 2007 632 634
3. S. Laporte, P. Mismetti, H. Decousus, F. Uresandi, R. Otero, J.L. Lobo, and M. Monreal Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry Circulation 117 13 2008 1711 1716
4. A.A. Khorana, M.R. Dalal, J. Lin, and G.C. Connolly Health care costs associated with venous thromboembolism in selected high-risk ambulatory patients with solid tumors undergoing chemotherapy in the United States Clinicoeconom Outcomes Res 5 2013 101 108
5. P. Prandoni, J. Trujillo-Santos, and T. Surico et al. Recurrent thromboembolism and major bleeding during oral anticoagulant therapy in patients with solid cancer: findings from the RIETE registry Haematologica 93 9 2008 1432 1434
6. A. Khorana, and G. Connolly Assessing risk of venous thromboembolism in the patient with cancer J Clin Oncol 27 29 2009 4839 4847
7. L.A. Menapace, D.R. Peterson, A. Berry, T. Sousou, and A.A. Khorana Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer Thromb Haemost 106 2 2011 371 378
8. A.A. Khorana, M. Dalal, J. Lin, and G.C. Connolly Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States Cancer 119 3 2013 648 655
9. A.A. Khorana, C.W. Francis, E. Culakova, and G.H. Lyman Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study Cancer 104 12 2005 2822 2829
10. R. Simanek, R. Vormittag, and C. Ay et al. High platelet count associated with venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS) J Thromb Haemost 8 1 2010 114 120
11. A.A. Khorana, N.M. Kuderer, E. Culakova, G.H. Lyman, and C.W. Francis Development and validation of a predictive model for chemotherapy-associated thrombosis Blood 111 10 2008 4902 4907
12. G. Agnelli, D.J. George, and A.K. Kakkar et al. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer N Engl J Med 366 7 2012 601 609
13. D. George, G. Agnelli, W. Fisher, and A. Kakkar et al. Venous thromboembolism (VTE) prevention with semuloparin in cancer patients initiating chemotherapy: benefit-risk assessment by VTE risk in SAVE-ONCO Blood 2011 118
14. M. Mandala, M. Clerici, and I. Corradino et al. Incidence, risk factors and clinical implications of venous thromboembolism in cancer patients treated within the context of phase I studies: the 'SENDO experience Ann Oncol 23 6 2012 1416 1421
15. C. Ay, D. Dunkler, C. Marosi, and A.L. Chiriac et al. Prediction of venous thromboembolism in cancer patients Blood 116 24 2010 5377 5382
16. R.A. Moore, N. Adel, and E. Riedel et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis J Clin Oncol 29 25 2011 3466 3473
17. G.J. Caine, G.Y. Lip, P.S. Stonelake, P. Ryan, and A.D. Blann Platelet activation, coagulation and angiogenesis in breast and prostate carcinoma Thromb Haemost 92 1 2004 185 190
18. G. Cella, M. Marchetti, and F. Vianello et al. Nitric oxide derivatives and soluble plasma selectins in patients with myeloproliferative neoplasms Thromb Haemost 104 1 2010 151 156
19. L. Li, P. Li, Y.Q. Yang, H. Zhang, P. Ai, F. Wang, Y. Jiang, L.Q. Zou, X. Yan, and F. Luo [sCD40L, sP-selectin and sICAM-1 plasma levels in nasopharyngeal carcinoma] Sichuan Da Xue Xue Bao Yi Xue Ban 40 3 2009 513 516
20. J. Huang, C. Jochems, and T Talaie et al. Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role Blood 120 15 2012 3030 3038
21. A. Mielczarek-Palacz, J. Sikora, Z. Kondera-Anasz, and G. Hauza Imbalance in serum soluble CD30/CD30L and CD40/CD40L systems are associated with ovarian tumors Hum Immunol 74 1 2013 70 74
22. J.E. Peterson, D. Zurakowski, and J.E. Italiano Jr. et al. VEGF, PF4 and PDGF are elevated in platelets of colorectal cancer patients Angiogenesis 15 2 2012 265 273
23. N.M. Cooke, K. Egan, and S. McFadden et al. Increased platelet reactivity in patients with late-stage metastatic cancer Cancer Med 2 4 2013 564 570
24. M. Kedzierska, U. Czernek, K. Szydlowska-Pazera, P. Potemski, J. Piekarski, A. Jeziorski, and B. Olas The changes of blood platelet activation in breast cancer patients before surgery, after surgery, and in various phases of the chemotherapy Platelets 24 6 2013 462 468
25. A.D. Blann, and G.Y. Lip Hypothesis: is soluble P-selectin a new marker of platelet activation? Atherosclerosis 128 2 1997 135 138
26. C. Ay, R. Simanek, and R. Vormittag et al. High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients - results from the Vienna Cancer and Thrombosis Study (CATS) Blood 112 2008 2703 2708
27. J. Vandercappellen, J. Van Damme, and S. Struyf The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer Cytokine Growth Factor Rev 22 1 2011 1 18
28. K.E. Poruk, M.A. Firpo, and L.M. Huerter et al. Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma Cancer Epidemiol Biomarkers Prev 19 10 2010 2605 2610
29. C.B. Thompson, K.A. Eaton, S.M. Princiotta, C.A. Rushin, and C.R. Valeri Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity, and function Br J Haematol 50 3 1982 509 519
30. C.J. Boos, G.D. Beevers, and G.Y. Lip Assessment of platelet activation indices using the ADVIATM 120 amongst 'high-risk' patients with hypertension Ann Med 39 1 2007 72 78
31. E. Coban, F. Bostan, and M. Ozdogan The mean platelet volume in subjects with impaired fasting glucose Platelets 17 1 2006 67 69
32. Y. Tavil, N. Sen, H.U. Yazici, F. Hizal, A. Abaci, and A. Cengel Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease Thromb Res 120 2 2007 245 250
33. J. Riedl, A. Kaider, E.M. Reitter, and C. Marosi et al. Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS) Thromb Haemost 111 2013 4
34. B. Shao, M.G. Wahrenbrock, and L. Yao et al. Carcinoma mucins trigger reciprocal activation of platelets and neutrophils in a murine model of Trousseau syndrome Blood 118 15 2011 4015 4023
35. V. Papayannopoulos, K.D. Metzler, A. Hakkim, and A. Zychlinsky Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps J Cell Biol 191 3 2010 677 691
36. S.R. Clark, A.C. Ma, and S.A. Tavener et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood Nat Med 13 4 2007 463 469
37. T.A. Fuchs, A. Brill, and D. Duerschmied et al. Extracellular DNA traps promote thrombosis Proc Natl Acad Sci U S A 107 36 2010 15880 15885
38. M.L. von Bruhl, K. Stark, and A. Steinhart et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo J Exp Med 209 4 2012 819 835
39. M. Demers, and D.D. Wagner Neutrophil extracellular traps: a new link to cancer-associated thrombosis and potential implications for tumor progression Oncoimmunology 2 2 2013 e22946
40. A. Brill, T.A. Fuchs, and A.K. Chauhan et al. von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models Blood 117 4 2011 1400 1407
41. K. Vanschoonbeek, M.A. Feijge, and R.J. Van Kampen et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics J Thromb Haemost 2 3 2004 476 484
42. K. Presseizen, Z. Friedman, H. Shapiro, J. Radnay, and M.H. Ellis Phosphatidylserine expression on the platelet membrane of patients with myeloproliferative disorders and its effect on platelet-dependent thrombin formation Clin Appl Thromb Hemost 8 1 2002 33 39
43. N.S. Barteneva, E. Fasler-Kan, M. Bernimoulin, J.N. Stern, E.D. Ponomarev, L. Duckett, and I.A. Vorobjev Circulating microparticles: square the circle BMC Cell Biol 14 2013 23
44. L. Bidot, W. Jy, C. Bidot Jr., J.J. Jimenez, V. Fontana, L.L. Horstman, and Y.S. Ahn Microparticle-mediated thrombin generation assay: increased activity in patients with recurrent thrombosis J Thromb Haemost 6 6 2008 913 919
45. N. Morel, O. Morel, X. Delabranche, L. Jesel, F. Sztark, P. Dabadie, J.M. Freyssinet, and F. Toti [Microparticles during sepsis and trauma. A link between inflammation and thrombotic processes] Ann Fr Anesth Reanim 25 9 2006 955 966
46. C. Amin, N. Mackman, and N.S. Key Microparticles and cancer Pathophysiol Haemost Thromb 36 3-4 2008 177 183
47. J. Thaler, C. Ay, and H. Weinstabl et al. Circulating procoagulant microparticles in cancer patients Ann Hematol 90 4 2011 447 453
48. X. Wang, M.Y. Hsu, T.E. Steinbacher, T.M. Monticello, and W.A. Schumacher Quantification of platelet composition in experimental venous thrombosis by real-time polymerase chain reaction Thromb Res 119 5 2007 593 600
49. T.A. Brighton, J.W. Eikelboom, and K. Mann et al. Low-dose aspirin for preventing recurrent venous thromboembolism N Engl J Med 367 21 2012 1979 1987
50. C. Becattini, G. Agnelli, and A. Schenone et al. Aspirin for preventing the recurrence of venous thromboembolism N Engl J Med 366 21 2012 1959 1967
51. L.A. Castellucci, C. Cameron, and G. Le Gal et al. Efficacy and safety outcomes of oral anticoagulants and anti-platelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis BMJ 347 2013 f5133
52. M. Gent, J. Hirsh, and J.S. Ginsberg et al. Low-molecular-weight heparinoid orgaran is more effective than aspirin in the prevention of venous thromboembolism after surgery for hip fracture Circulation 93 1 1996 80 84
53. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355(9212):1295- 302.
54. G.H. Westrich, F. Bottner, R.E. Windsor, R.S. Laskin, S.B. Haas, and T.P. Sculco VenaFlow plus Lovenox vs VenaFlow plus aspirin for thromboembolic disease prophylaxis in total knee arthroplasty J Arthroplasty 21 6 Suppl 2 2006 139 143
55. D.R. Anderson, M.J. Dunbar, and E.R. Bohm et al. Aspirin versus low-molecular-weight heparin for extended venous thromboembolism prophylaxis after total hip arthroplasty: a randomized trial Ann Intern Med 158 11 2013 800 806
56. R. Landolfi, R. Marchioli, and J. Kutti et al. Efficacy and safety of low-dose aspirin in polycythemia vera N Engl J Med 350 2 2004 114 124
57. A. Palumbo, M. Cavo, and S. Bringhen et al. Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial J Clin Oncol 29 8 2011 986 993
58. A. Larocca, F. Cavallo, and S. Bringhen et al. Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide Blood 119 4 2012 933 939
59. A. Shai, H.S. Rennert, and O. Lavie et al. Statins, aspirin and risk of venous thromboembolic events in breast cancer patients J Thromb Thrombolysis Epub 24 Oct 2013
60. A. Shai, H.S. Rennert, G. Rennert, S. Sagi, M. Leviov, and O. Lavie Statins, aspirin and risk of thromboembolic events in ovarian cancer patients Gynecol Oncol 133 2014 304 308